Author Response to Letter to Editor regarding “Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?”
- Autori: Campisi, Giuseppina; Mauceri, Rodolfo; Coppini, Martina; Bedogni, Alberto; Bertoldo, Francesco; Fusco, Vittorio
- Anno di pubblicazione: 2024
- Tipologia: Lettera
- OA Link: http://hdl.handle.net/10447/651773
Abstract
Dear Editor, we have read with great interest the Letter to the Editor by Cordova et al. “Why are osteopoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral care?”. We strongly agree with the Authors claiming for “differentiated guidelines for osteoporosis and oncology patients” regarding their risk of Antiresorptive-Related Osteonecrosis of the the Jaw (ARONJ), that is the main form of what is recently known as Medication-Related Osteonecrosis of the Jaw (MRONJ).